Amyloid-β probes: Review of structure–activity and brain-kinetics relationships

The number of people suffering from Alzheimer’s disease (AD) is expected to increase dramatically in the coming years, placing a huge burden on society. Current treatments for AD leave much to be desired, and numerous research efforts around the globe are focused on developing improved therapeutics....

Full description

Bibliographic Details
Main Authors: Todd J. Eckroat, Abdelrahman S. Mayhoub, Sylvie Garneau-Tsodikova
Format: Article
Language:English
Published: Beilstein-Institut 2013-05-01
Series:Beilstein Journal of Organic Chemistry
Subjects:
Online Access:https://doi.org/10.3762/bjoc.9.116
id doaj-3b45097ef8b24e50af351d89ba473627
record_format Article
spelling doaj-3b45097ef8b24e50af351d89ba4736272021-02-02T04:44:49ZengBeilstein-InstitutBeilstein Journal of Organic Chemistry1860-53972013-05-01911012104410.3762/bjoc.9.1161860-5397-9-116Amyloid-β probes: Review of structure–activity and brain-kinetics relationshipsTodd J. Eckroat0Abdelrahman S. Mayhoub1Sylvie Garneau-Tsodikova2Department of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, United StatesLife Sciences Institute and Department of Medicinal Chemistry, University of Michigan, 210 Washtenaw Ave, Ann Arbor, MI, 48109-2216, United StatesDepartment of Pharmaceutical Sciences, University of Kentucky, 789 South Limestone Street, Lexington, KY, 40536-0596, United StatesThe number of people suffering from Alzheimer’s disease (AD) is expected to increase dramatically in the coming years, placing a huge burden on society. Current treatments for AD leave much to be desired, and numerous research efforts around the globe are focused on developing improved therapeutics. In addition, current diagnostic tools for AD rely largely on subjective cognitive assessment rather than on identification of pathophysiological changes associated with disease onset and progression. These facts have led to numerous efforts to develop chemical probes to detect pathophysiological hallmarks of AD, such as amyloid-β plaques, for diagnosis and monitoring of therapeutic efficacy. This review provides a survey of chemical probes developed to date for AD with emphasis on synthetic methodologies and structure–activity relationships with regards to affinity for target and brain kinetics. Several probes discussed herein show particularly promising results and will be of immense value moving forward in the fight against AD.https://doi.org/10.3762/bjoc.9.116Alzheimer’s diseasein vivo detectionnear-infrared fluorescence probesPET/SPECT imagingradioactive probes
collection DOAJ
language English
format Article
sources DOAJ
author Todd J. Eckroat
Abdelrahman S. Mayhoub
Sylvie Garneau-Tsodikova
spellingShingle Todd J. Eckroat
Abdelrahman S. Mayhoub
Sylvie Garneau-Tsodikova
Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
Beilstein Journal of Organic Chemistry
Alzheimer’s disease
in vivo detection
near-infrared fluorescence probes
PET/SPECT imaging
radioactive probes
author_facet Todd J. Eckroat
Abdelrahman S. Mayhoub
Sylvie Garneau-Tsodikova
author_sort Todd J. Eckroat
title Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
title_short Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
title_full Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
title_fullStr Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
title_full_unstemmed Amyloid-β probes: Review of structure–activity and brain-kinetics relationships
title_sort amyloid-β probes: review of structure–activity and brain-kinetics relationships
publisher Beilstein-Institut
series Beilstein Journal of Organic Chemistry
issn 1860-5397
publishDate 2013-05-01
description The number of people suffering from Alzheimer’s disease (AD) is expected to increase dramatically in the coming years, placing a huge burden on society. Current treatments for AD leave much to be desired, and numerous research efforts around the globe are focused on developing improved therapeutics. In addition, current diagnostic tools for AD rely largely on subjective cognitive assessment rather than on identification of pathophysiological changes associated with disease onset and progression. These facts have led to numerous efforts to develop chemical probes to detect pathophysiological hallmarks of AD, such as amyloid-β plaques, for diagnosis and monitoring of therapeutic efficacy. This review provides a survey of chemical probes developed to date for AD with emphasis on synthetic methodologies and structure–activity relationships with regards to affinity for target and brain kinetics. Several probes discussed herein show particularly promising results and will be of immense value moving forward in the fight against AD.
topic Alzheimer’s disease
in vivo detection
near-infrared fluorescence probes
PET/SPECT imaging
radioactive probes
url https://doi.org/10.3762/bjoc.9.116
work_keys_str_mv AT toddjeckroat amyloidbprobesreviewofstructureactivityandbrainkineticsrelationships
AT abdelrahmansmayhoub amyloidbprobesreviewofstructureactivityandbrainkineticsrelationships
AT sylviegarneautsodikova amyloidbprobesreviewofstructureactivityandbrainkineticsrelationships
_version_ 1724305077208875008